Edwards Lifesciences Corporation
NYSE:EWMedical - Devices
+$0.49 today
- Market cap
- $60.51B
- Beta
- 0.87
- P/E (TTM)
- 46.2
- EPS (TTM)
- $1.89
Volume 3.92M
Average 5.02M
EW EBITDA Margin
EBITDA as a percentage of revenue.
Edwards Lifesciences CorporationNYSE: EW
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 32.3%
EBITDA Margin was 32.3% in Q2 FY2026, up 6.2 pp from a year earlier. On a trailing-twelve-month basis it was 24.3%, down 7.1 pp year over year. Over 3 fiscal years it narrowed by 12.4 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 21 analysts of 31.5% for the fiscal year ending Dec 2026, up from 23.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 32.3%+2.0 pp QoQ
- Last fiscal yearDec 2025
- 23.6%-8.1 pp YoY
- LTMJun 2026
- 24.3%-7.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.2 pp | +5.6 pp | -0.6 pp |
| 1 year | -8.1 pp | +7.9 pp | +16.0 pp |
| 3 years | -12.4 pp | +8.8 pp | +21.1 pp |
| 5 years | +10.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 23.6%
- Year-over-year change
- -8.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.6% | -8.1pp |
| FY2024 | 2024-12-31 | 31.7% | +1.0pp |
| FY2023 | 2023-12-31 | 30.6% | -5.3pp |
| FY2022 | 2022-12-31 | 35.9% | +0.3pp |
| FY2021 | 2021-12-31 | 35.6% | — |
EBITDA Margin vs competitors
How EW compares with its peers on the latest reported figures
- EW's LTM Jun 2026 EBITDA Margin of 24.3% is the 2nd highest of the 6 companies compared; the peer median is 14.2%.
- Its year-over-year change of -7.1 pp is the 5th highest of 6, against a peer median of -0.4 pp.
- Over three fiscal years its change of -12.4 pp compares with a peer median of +6.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 36.2% | -2.8 pp | +7.9 pp | |
| LTM Jun 2026 | 24.3% | -7.1 pp | -12.4 pp | |
| LTM Jun 2026 | 14.8% | -0.4 pp | +12.4 pp | |
| LTM Mar 2026 | 14.2% | +5.1 pp | +6.3 pp | |
| LTM Sep 2026 | 14.0% | +20.0 pp | -12.4 pp | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -5021.0% | -1760.3 pp | -3924.4 pp |
| Peer median (excluding EW) | 14.2% | -0.4 pp | +6.3 pp | |
Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.23B | 5.38B | 5.01B | 5.44B | 6.07B |
| Cost of Revenue | 1.23B | 1.17B | 1.04B | 1.12B | 1.33B |
| Gross Profit | 4.01B | 4.22B | 3.97B | 4.32B | 4.74B |
| Gross Margin | 76.6% | 78.3% | 79.3% | 79.5% | 78.1% |
| Research & Development | 903.1M | 945.2M | 962.9M | 1.05B | 1.08B |
| Selling, General & Admin | 1.49B | 1.57B | 1.58B | 1.79B | 2.09B |
| Operating Expenses | 2.4B | 2.51B | 2.55B | 2.94B | 3.1B |
| Depreciation & Amortization | 134.8M | 139.6M | 144.9M | 155.2M | 156.6M |
| EBITDA | 1.86B | 1.93B | 1.53B | 1.72B | 1.43B |
| EBITDA Margin | 35.6% | 35.9% | 30.6% | 31.7% | 23.6% |
| Operating Income | 1.61B | 1.7B | 1.43B | 1.38B | 1.64B |
| Operating Margin | 30.8% | 31.6% | 28.5% | 25.3% | 27.0% |
| Interest Income | 17.4M | 35.5M | 67.2M | 120.3M | 148.4M |
| Interest Expense | 24.8M | 26.2M | 17.6M | 19.8M | 0 |
| Other Income / Expenses | 91.6M | 65M | (54.9M) | 169.4M | (363.3M) |
| Income Before Tax | 1.7B | 1.77B | 1.37B | 1.55B | 1.27B |
| Pre-Tax Margin | 32.5% | 32.8% | 27.4% | 28.5% | 21.0% |
| Income Tax Expense | 198.9M | 245.5M | 152.4M | 152.1M | 216.9M |
| Net Income | 1.5B | 1.52B | 1.4B | 4.17B | 1.07B |
| Net Margin | 28.7% | 28.3% | 28.0% | 76.7% | 17.7% |
| EPS (Basic) | 2.41 | 2.46 | 2.31 | 6.98 | 1.84 |
| EPS (Diluted) | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 |
| Weighted Avg Shares | 623.3M | 619M | 606.7M | 597.7M | 584.8M |
| Weighted Avg Shares (Diluted) | 631.2M | 624.2M | 609.4M | 599.3M | 585.8M |
Edwards Lifesciences Corporation
NYSE:EW
Intrinsic Alpha fair value
Locked
Current Price
$105.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.